Insider Trading June 25, 2026 05:45 PM

TTM Technologies COO Executes $611K Stock Sale Amid Strategic Expansion

James P. Walsh's transaction under a 10b5-1 plan coincides with significant corporate developments, including European acquisitions and index reclassification.

By Hana Yamamoto
Share
Twitter Reddit Facebook LinkedIn
TTMI

James P. Walsh, Chief Operating Officer at TTM Technologies Inc. (NASDAQ: TTMI), sold 2,916 shares totaling $611,766 on June 23, 2026. The transaction, executed under a pre-established 10b5-1 trading plan, was designated to cover tax obligations from restricted stock unit vesting. The sale occurs while the company navigates major growth milestones, including European market expansion through acquisitions of Swiss Technology Group AG and ILFA GmbH, and a transition from the Russell 2000 to the Russell 1000 Index.

TTM Technologies COO Executes $611K Stock Sale Amid Strategic Expansion
TTMI
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • James P. Walsh sold 2,916 shares for $611,766 under a 10b5-1 plan to cover tax liabilities from RSU vesting.
  • TTM Technologies is acquiring Swiss Technology Group AG and ILFA GmbH to expand its European medical and aerospace footprint.
  • The company is transitioning from the Russell 2000 to the Russell 1000 Index, reflecting significant growth in market capitalization.

James P. Walsh, serving as Chief Operating Officer of TTM Technologies Inc. (NASDAQ: TTMI), completed a stock transaction on June 23, 2026, disposing of 2,916 shares of common stock. The total value of this divestment reached $611,766. The execution of these sales was governed by a 10b5-1 trading plan that was established on February 24, 2026. The specific purpose of this automated trading arrangement was to satisfy tax liabilities linked to the vesting of restricted stock units. The shares were liquidated at varying price points between $201.89 and $213.73.

Post-transaction, Mr. Walsh maintains a direct holding of 30,633 shares of TTM Technologies common stock. The timing of this sale aligns with the stock trading near its 52-week peak of $223.83. This valuation point follows a substantial 435% return over the preceding year. Market analysis indicates that the stock is currently priced above its fair value, positioning it within lists of overvalued equities. Investors seeking further data on TTMI may access additional tips or a comprehensive Pro Research Report through InvestingPro.

Concurrently, TTM Technologies is advancing strategic growth initiatives. The company has disclosed plans to acquire Swiss Technology Group AG and ILFA GmbH through separate all-cash deals, subject to regulatory clearance. These acquisitions are designed to increase TTM's market presence in Europe, with a specific focus on the medical and aerospace sectors. Furthermore, the company is scheduled to transition from the Russell 2000 Index to the Russell 1000 Index. This reclassification will take effect after market close on June 26, 2026, reflecting the company's expansion into the ranks of the largest publicly traded U.S. corporations.

Operational expansion continues with the launch of a new $130 million Ultra-High-Density Interconnect printed circuit board manufacturing facility in Syracuse, New York. This project, partially financed by a $30 million investment from the U.S. Department of Defense, is intended to support aerospace and defense applications. Additionally, the Mini-Xinger product line has achieved AEC-Q200 qualification accreditation, confirming its suitability for automotive and high-reliability sectors. These developments underscore TTM's ongoing efforts to broaden its capabilities and market reach.

Risks

  • Acquisitions of Swiss Technology Group AG and ILFA GmbH are pending regulatory approvals, introducing execution risk.
  • Stock valuation metrics suggest potential overvaluation relative to fair value, despite recent price appreciation.
  • Integration of new facilities and product lines requires continued capital expenditure and operational discipline.

More from Insider Trading

Trulieve CEO Kim Rivers Executes $8.9 Million Share Liquidation Under Pre-Arranged Trading Plan Jun 25, 2026 Aditxt Shareholder Liquidates Entire Stake as Stock Plummets Amid Corporate Restructuring Jun 25, 2026 EverCommerce Executive Transaction and Q1 Financial Review Jun 25, 2026 Nurix Therapeutics CSO Gwenn Hansen Sells Stock Amid Clinical Progress and Roche Partnership Jun 25, 2026 Nurix Therapeutics Executive Sells Shares Amid Clinical Milestones and Strategic Partnership Jun 25, 2026